Search

Clofibrate and m-Inositolnicotinate in a daily dosage of 1,5 g Clofibrate and 1,2 g m-Inositolnicotinate during long term treatment effected a good triglyceride fall in all three lipoprotein fractions, especially in VLDL. The changing of the hyperlipoproteinemia phenotypus IV to the phenotypus IIb or IIa under monotherapy with Clofibrate or clofibrinic acid could not be avoided by the combination of Clofibrate with m-Inositolnicotinate. Approximately every fourth hyperlipoproteinemia phenotypus IV or V, treated with a combination therapy, had an increase of beta-Cholesterol in the pathological range of more than 210 mg/dl. The combination of Clofibrate with nicotinic acid is not of greater value than the monotherapy with Clofibrate (Atromid S). A combination of Clofibrate and nicotinic acid is useful when pure nicotinic acid (3 to 4g/daily) or its esters, for example m-Inositol-nicotinate (4 to 6g/daily) or beta-Pyridylcarbinol (800 to 1200 mg/daily) are administered in therapeutic doses. With the increased dosage of nicotinic acid, one must expect a large "drop out" of these appropriate hyperlipoproteinemia patients because of the side-effects resulting from this particular treatment with nicotinic acid.

The absorption, blood level and renal excretion of chlorphenoxyisobutyric acid (clofibric acid) were examined following oral dosage of the magnesium salt (magnesium clofibrate) in a combination preparation containing meso-inositol hexanicotinate. Absorption of clofibric acid was found to be identical with that obtained with ethyl-alpha-p-chlorphenoxyisobutyrate (Clofibrate) reaching almost 100%. After dosage with the combination preparation, the maximum blood level of clofibric acid was achieved after 2 hours, in contrast to 4 hours for Clofibrate. No accumulation of clofibric acid in the blood was found after 60 days treatment with combination preparation at a daily dosage of 3 tablets. Urinary excretion of clofibric acid for both the combination drug and Clofibrate was 90% in 48 hours.